'Clarity about lack of clarity' on health reform helps acquisition pipeline
Oct 22, 2009 7:26 PM
Gene Overholt, a gatroenterology pioneer who has been medical director of AmSurg since 1992 and was a board member of the Nashville company until this past spring, has been elected to the board of CRH Medical, a Vancouver-based company (Toronto Ticker: CRM) that develops hemorrhoid treatments.
Sep 25, 2009 12:14 AM
The hospital giant has amended its financial statements to comply with FAS 160, an accounting rule that became effective Jan. 1 and calls for a change in the way companies represent outsiders' stakes in controlled subsidiaries. The restatement doesn't affect net income or shareholders' equity numbers, but does boost the company's 2006-2008 cash flows from operations by $504 million. HCA's move follows that of AmSurg last week. Hmm, think there will be others?
Aug 17, 2009 9:41 AM
The surgery center operator said it incorrectly applied a new accounting rule governing minority stakes in joint ventures. The rule, which went into effect at the start of this year, requires AmSurg (Ticker: AMSG) break out the equity held by other parties in its joint ventures and affects about $3 million. See the amended numbers here.
Aug 11, 2009 6:43 AM
Healthways lands its first WholeHealth contract, AmSurg taps a new chairman
Jul 23, 2009 3:32 PM
Ambulatory surgery center operator AmSurg, which yesterday received an upgrade to 'Buy' from TheStreet.com Ratings, this morning was downgraded to 'Neutral' by Whit Mayo from Robert W. Baird
A Robert W. Baird analyst downgraded outpatient surgery center operator AmSurg Corp. Tuesday, citing a lack of upcoming catalysts and the likelihood the stock will remain flat. Baird analyst Whit Mayo lowered his rating to "Neutral" from "Outperform" but lowered his price target to $23 from $24, saying the share value has returned to a more reasonable level. "Thus, outside of a re-acceleration in earnings, we see few significant catalysts and expect the stock to trade sideways," he wrote in a note to investors.
Jul 7, 2009 10:10 AM
TheStreet.com Ratings announced early this morning that it has upgraded surgery center operator AmSurg to "Buy"
The numbers: Fiscal first-quarter revenue rose 12% to $163 million as net income climbed 7.8% to $13 million and earnings per share ascended 8.1% to 40 cents, extending a growth streak to nine quarters. The cash balance is ample with $31 million of reserves. The debt-to-equity ratio is low at 0.6. The net margin is wide at 7.7% but has shed 30 basis points since last year's first quarter. The stock: Amsurg is down 10% in 2009, trading at a price-to-earnings ratio of about 13. The company has a market capitalization of $670 million.
Jul 6, 2009 11:39 AM
Analysts at Bank of America have begun tracking a number of Middle Tennessee health care companies with mostly favorable ratings. Getting 'buy' recommendations are Community Health and Psych Solutions. Rated 'neutral' for now are Brookdale and LifePoint. The only local 'underperform' in BofA's crop is AmSurg. With the exception of Brookdale, the companies' stocks are flat or higher this morning.
Jun 17, 2009 9:39 AM
Vanderbilt dorm renovations, AmSurg investing in Burton Hills, more townhomes, and more...
Apr 24, 2009 1:39 PM